Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 clinical study titled Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301). The study aims to evaluate progression-free survival in patients with KRAS p.G12C mutated metastatic colorectal cancer, comparing a combination of sotorasib, panitumumab, and FOLFIRI against FOLFIRI with or without bevacizumab-awwb.
The study tests two treatment arms: Arm A involves sotorasib, panitumumab, and FOLFIRI, while Arm B involves FOLFIRI with or without bevacizumab-awwb. Sotorasib is taken orally daily, while panitumumab, FOLFIRI, and bevacizumab-awwb are administered intravenously every two weeks.
This interventional study follows a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. Participants are randomly assigned to either treatment group to assess the effectiveness of the interventions.
The study began on July 17, 2024, with the last update submitted on July 24, 2025. These dates are crucial as they indicate the study’s progression and timeline for potential results.
For investors, this study could have significant implications for Amgen’s stock performance, as positive outcomes may enhance market confidence and competitive positioning in the oncology sector. The study’s progress and results could influence investor sentiment and industry dynamics, particularly in the treatment of metastatic colorectal cancer.
The study is currently recruiting, with further details available on the ClinicalTrials portal.